AI-Reviewed Research, Clinical Excellence & Evidence-Based Practice in Aesthetic Medicine— Curated and reviewed by practising aesthetic clinicians
Aesthetic Intelligence · Industry News
Industry News for Aesthetic Medicine
Regulatory updates, product alerts, peer-reviewed research highlights, and HSI announcements — filtered by region. Editorial commentary, not promotional.
New CQC-registered medical cannabis clinic opens as UK private market passes 140,000 patients
A new Care Quality Commission-registered medical cannabis clinic, Medecan, has launched in the UK, co-founded by NHS GP and chief medical officer Dr David Eccleston, offering a regulated prescribing pathway for chronic pain, cancer, inflammatory and neurological disorders, PTSD, anxiety and sleep disorders. The opening comes as Prohibition Partners estimates the UK medical cannabis market at £302–389 million with more than 140,000 patients in 2026. Harley Street Institute has published a business-facing review of what it costs to set up a compliant clinic, how pricing works, and the pros and cons for clinicians considering entry.
DHSC consults on six new safeguards for commercial sunbeds in England
The Department of Health and Social Care opened a consultation on 22 May 2026 (closed 14 August 2026) proposing mandatory photo-ID age verification, staff supervision, a ban on selling or hiring sunbed devices to under-18s, mandatory pre-sale health risk information, certified protective eyewear, and a prohibition on promoting unproven health benefits. An outright commercial ban was not consulted on, despite the British Photodermatology Group and British Association of Dermatologists calling for one. Harley Street Institute has published a four-lens review of the health, economic and psychological evidence.
European Commission approves Boey (trenibotulinumtoxinE), the first serotype E neurotoxin in Europe
Allergan Aesthetics announced on 17 July 2026 that the European Commission has approved Boey (trenibotulinumtoxinE) across all 30 EEA countries for the temporary improvement of moderate to severe glabellar lines in adults where these have an important psychological impact. It is the first rapid-onset, short-duration botulinum neurotoxin serotype E licensed in Europe, with onset observed as early as eight hours and effect typically resolving within two to three weeks; approval follows Health Canada authorisation in June 2026. Harley Street Institute has published a review explaining why serotype E duration is set by its SNAP-25 cleavage site and light-chain persistence rather than by dose.
MHRA strengthens iatrogenic botulism warnings for all botulinum toxin type A products
The Medicines and Healthcare products Regulatory Agency has updated product information and patient leaflets across all botulinum toxin type A products following rare reports of iatrogenic botulism, where toxin effect extends beyond the treated area. Symptoms — difficulty swallowing, slurred speech, breathing difficulty and generalised weakness — typically appear within four to eight days but may take up to four weeks. Harley Street Institute has published a commentary arguing that reported cosmetic dysphagia is concentrated in platysma treatment and reflects dose, depth and technique rather than unpredictable spread.
Aesthetic Intelligence — Volume 1, Issue 6 now online
Issue 6 leads with a critical evidence review of the therapeutic peptide landscape, alongside articles on necrosis management, dermal filler complications, and migraine prevention with botulinum toxin.
Teoxane unveils babyGLOW subdermal injection technique at IMCAS Paris 2026
Aesthetic manufacturer Teoxane presented the babyGLOW technique — a standardised, anatomy-based subdermal injection approach using Teosyal Puresense Redensity 1 — at the International Master Course on Ageing Science (IMCAS) in Paris. The method, refined with a board of over 20 expert injectors across six countries, is designed to support consistent product distribution while avoiding facial danger zones. Harley Street Institute notes that anatomy-guided subdermal placement has been integral to its teaching curriculum for several years.
The Harley Street Institute’s open-access journal Aesthetic Intelligence has been formally registered with ISSN 2979-8116, supporting long-term indexing, citation, and archival permanence.
MHRA reiterates position on unlicensed therapeutic peptides
The Medicines and Healthcare products Regulatory Agency has reissued guidance clarifying that BPC-157, TB-500, and similar research peptides remain unlicensed for human use in the UK, with medicinal claims constituting an offence under the Human Medicines Regulations 2012.
The US Food and Drug Administration has updated its consumer and clinician alert on counterfeit Botox vials circulating outside the licit supply chain, following further confirmed adverse events including botulism-like symptoms requiring hospitalisation.
JAMA Dermatology: randomised trial of polynucleotide skin boosters
A multi-centre randomised controlled trial published in JAMA Dermatology reports statistically significant improvements in dermal hydration and elasticity at twelve weeks following a three-session polynucleotide protocol versus saline control.
HPRA strengthens vigilance reporting for cosmetic injectables
Ireland’s Health Products Regulatory Authority has expanded post-market surveillance requirements for hyaluronic-acid fillers and botulinum toxin products distributed in the Republic, with clinicians encouraged to report adverse events through the online portal.
JCCP welcomes Department of Health licensing scheme progress
The Joint Council for Cosmetic Practitioners reports that secondary legislation under Section 180 of the Health and Care Act 2022 is progressing, moving toward statutory licensing for non-surgical cosmetic procedures in England.
The Lancet Neurology: real-world data on onabotulinumtoxinA for chronic migraine
A large prospective registry analysis confirms sustained reduction in monthly headache days under the PREEMPT protocol, with response rates broadly mirroring pivotal trial outcomes across diverse populations.
ASDS publishes updated consensus on vascular occlusion management
The American Society for Dermatologic Surgery has released a 2026 consensus statement on the recognition and stepwise management of intravascular filler events, reinforcing hyaluronidase dosing and ophthalmology referral thresholds.
GMC updates CPD expectations for doctors practising aesthetic medicine
The General Medical Council has issued supplementary guidance reinforcing that doctors practising in cosmetic interventions are expected to evidence CPD relevant to their scope of practice — a domain in which structured AiCE-aligned activity contributes.
HIQA consults on private clinic standards including non-surgical aesthetics
The Health Information and Quality Authority has opened a consultation that, for the first time, explicitly references non-surgical aesthetic procedures within proposed national standards for private healthcare settings.
FDA announces intent to restrict non-approved GLP-1 compounding
The US Food and Drug Administration has declared decisive steps to restrict access to GLP-1 ingredients for non-FDA-approved compounded drugs, and on 30 April 2026 proposed removing semaglutide and tirzepatide from the 503B bulks list, citing stabilising branded supply.
MHRA approves stronger dosage of semaglutide for weight management
The Medicines and Healthcare products Regulatory Agency has approved a new maximum weekly dose of semaglutide up to 7.2mg for adults with obesity (BMI ≥30 kg/m²). The higher dose is administered as three consecutive 2.4mg injections following a structured escalation schedule, and does not apply to cardiovascular-risk indications.
The US Food and Drug Administration has approved Wegovy as the first once-daily oral GLP-1 weight-loss pill for chronic weight management in adults with obesity. Developed by Novo Nordisk, the tablet contains semaglutide and became available in US pharmacies from January 2026.
Industry news is curated by the HSI editorial board. Items summarise external regulatory, product, and peer-reviewed developments and link to primary sources. They do not constitute clinical guidance. For peer-reviewed analysis, see the main journal.